News
VOR
18.05
+3.80%
0.66
Vor Biopharma initial beneficial ownership filed by TCG Crossover GP II, LLC
Reuters · 2d ago
Vor Bio grants inducement equity awards to 9 new hires under Nasdaq rule
Reuters · 2d ago
VOR BIO REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 2d ago
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 3d ago
Vor Biopharma Price Target Raised to $15.00/Share From $9.00 by Wedbush
Dow Jones · 4d ago
Vor Biopharma Is Maintained at Neutral by Wedbush
Dow Jones · 4d ago
Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $15
Benzinga · 4d ago
Vor Bio price target raised to $15 from $9 at Wedbush
TipRanks · 4d ago
VOR BIOPHARMA INC <VOR.O>: WEDBUSH RAISES TARGET PRICE TO $15 FROM $9
Reuters · 4d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 4d ago
U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks
Reuters · 4d ago
Vor Bio price target lowered to $40 from $55 at Stifel
TipRanks · 5d ago
Vor Biopharma: Solid Clinical Execution and Strengthened Balance Sheet Support Buy Rating and Long-Term Growth Outlook
TipRanks · 5d ago
Vor Biopharma Q4 Adj. EPS $(1.63) Beats $(1.64) Estimate
Benzinga · 5d ago
Vor Biopharma Price Target Announced at $50.00/Share by Jefferies
Dow Jones · 5d ago
Vor Biopharma Initiated at Buy by Jefferies
Dow Jones · 5d ago
Vor Biopharma reports Q4 results
Seeking Alpha · 5d ago
Jefferies Initiates Coverage On Vor Biopharma with Buy Rating, Announces Price Target of $50
Benzinga · 5d ago
Vor Bio doses first patient in UPSTREAM SjD study
TipRanks · 5d ago
Vor Biopharma Q4 profit tops estimates on warrant fair value gain
Reuters · 5d ago
More
Webull provides a variety of real-time VOR stock news. You can receive the latest news about Vor Biopharma Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.